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ABSTRACT
Hemophilia therapeutics are evolving rapidly. Comprehensive care must also evolve to embrace
this change. Online tools and guidelines are widely available to optimize prophylaxis with
conventional clotting factor concentrates using an individual’s predicted pharmacokinetic
profile. Novel hemostatic agents (e.g. biphenotypic antibody) are also becoming widely
available, with other agents with differing mechanisms of action in final stages of trial.
Contemporary issues including challenges of prophylaxis; bleed treatment; laboratory
monitoring and inhibitor risk/surveillance are summarized in this narrative review, focusing
on how a re-personalization of education and treatment will be necessary to meet these
challenges of the rapidly changing therapeutic landscape.
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‘Personalization’ and ‘Stratified Medicine’ are commonly
used terms in many areas of contemporary medicine,
most notably oncology, aligning the power of
genomic dissection of disease subtypes (e.g. breast
cancer) to best match with an ever increasing portfolio
of molecular or targeted therapies. Hemophilia A care
has arguably always had a multidisciplinary, personali-
zation intent with the evolution of comprehensive
care, but only recently begun to implement individua-
lized pharmacokinetics (PK) into the formulation of
FVIII prophylaxis prescribing practices. The hemosta-
siologist/hematologist now appreciates the substantial
variation of time to baseline FVIII levels (48–109 h)
after a standard 30 u/kg dose of standard half-life
FVIII clotting factor concentrate (CFC) [1]. The avail-
ability of online tools implementing population phar-
macokinetic (popPK) algorithms now enables the
identification of an individual person with hemophilia
(PWH)’s own PK profile as a standard of care, with
recent ISTH SSC guidance on the subject [2,3]. Indivi-
dualized-PK guided dosing has delivered annualized
bleed rates (ABR) of zero in excess of 40% and even
>80% for spontaneous bleed freedom in clinical trial
settings [4,5]. Current attempts to optimise prophylaxis
benefit many PWH, but also identify a substantial min-
ority who continue to bleed despite such a personal-
ized approach. Arguably, this will become the
contemporary stratification step in hemophilia care
as the therapeutic landscape evolves. However, it
should also be remembered that the ABR metric,
although commonly used, is not the complete story
of protection for patients. The concept of subclinical
bleeding leading to musculoskeletal damage despite
no overt joint bleeds requires continued attention
[6,7].
The remaining important area to stratify hemophilia
care is the prediction of inhibitory antibody occurrence
and/or the outcome of immune tolerance induction. It
has long been known that the F8 mutation is relevant
in this area [8] and also now contributory to interpret-
ing the benefit of a plasma-derived fVIII CFC at the very
first exposure to treatment in a previously untreated
patient (PUP) [9]. The minority of individuals with less
disruptive F8 genotypes may benefit from a pdFVIII
over a recombinant product, but for the majority with
more disruptive mutations, including Intron 22 inver-
sion, this stratification on F8 alone does not hold [10].
Antibody affinity maturation and class switching to
IgG4 have been identified as an important step to dis-
criminate clinically meaningful inhibitory antibodies
from non-inhibitory or transient ones [11]. Multiple
additional immune-modulatory polymorphisms have
been identified [12,13,14,15] but not yet converted to
aid the stratification of early treatment choices in clini-
cal practice, not least that for the majority of baby boys
these markers are not available at the time of first treat-
ment. Studies are ongoing to further understand the
early molecular steps in inhibitor induction at first
exposure to CFC.
There is currently a rich pipeline of therapeutic
agents in clinical trials or early approval for hemophilia
treatment [16,17,18]. The majority have mechanisms of
action that modulate hemostasis, but the therapeutic
agents are not themselves factor replacements [19].
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Rather, they either mimic the hemostatic function of
the FVIII protein, e.g. biphenotypic antibody binding
factor IXa and X (emicizumab, Roche) [16] or modulate
the hemostatic equilibrium through interference with
regulatory molecules, e.g. antithrombin knockdown
(siRNA, Fitusiran, Sanofi) [17] or Tissue Factor Pathway
Inhibitor (TFPI) interference (e.g. Concizumab, Novo-
Nordisk) [18]. The apparent added values of all these
molecules are a combination of a less demanding
route of administration, subcutaneous (SC) rather
than intravenous (IV), and long half-lives that enable
both less frequent dosing (up to once a month)
together with a continuous hemostatic level of protec-
tion thought to be well into the mild hemophilia equiv-
alent range of FVIII activity (FVIII:C). However,
modulating the clotting cascade in these ways is not
without uncertainty and risk, recognizing the multiple
interactions between cascade molecules, and that
wild-type FVIII is arguably the most tightly regulated
molecule in the entire cascade. Although co-adminis-
tration of the bypassing agent (BPA) Factor Eight
Bypassing Activity (FEIBA, Takeda) with emicizumab is
thought as the likely precipitant of the unusual throm-
botic and Thrombotic MicroAngiopathic (TMA) events
seen in the HAVEN 1 emicizumab trial [16], the lack of
a necessary activation step and absence of negative
control (e.g. activated Protein C) for functional mimics
contrasts to the requirements for the wild-type FVIII
molecule. The pathophysiology of these TMA events
remains obscure and time to resolution uncertain.
Additionally, novel agents have half-lives that will
require weeks or months of wash out if needing to
be stopped electively or in an emergency in the
absence of any antidotes. Novel agents are not quan-
tifiable in any current, standard hemostatic assay,
whilst validated product-specific assays are yet to
become available. Risk of anti-drug antibodies (ADA)
against these agents appear to be low [16] but loss of
efficacy and a confirmed ADA case using emicizumab
highlights need for ADA surveillance strategies for all
new monoclonal therapies.
Novel agent efficacy appears to be sufficient for pro-
phylaxis, but not for maximal hemostatic protection for
serious trauma or major surgery. As such, we are enter-
ing an era of requiring different agents for baseline pro-
phylaxis and on-demand treatments. Conventional CFC
and BPA will remain the on-demand therapeutics of
choice in non-inhibitor and inhibitor settings respect-
ively. The absence of validated assays to give a clinician
a meaningful readout from patients’ plasma with simul-
taneous novel and conventional hemostatic agents on
board remains a concern, particularly for less experi-
enced clinicians or laboratory scientists who may not
be aware of these potential confounders to assay
interpretation and consequent risk to clinical manage-
ment. This further supports the assertion that these
new agents should be overseen by experienced
comprehensive care centers despite the convenience
of administration that paradoxically encourages
detachment from such an expert center in favor of a
more local, less specialist facility. It is notable that
both reported deaths in the novel agent trials (Emicizu-
mab and Fitusiran) occurred in facilities distant to their
comprehensive care trial centers [16].
Conversion to a continuous level of hemostatic pro-
tection equivalent to mild hemophilia with a novel
agent meets one of the prophylaxis challenges conven-
tional factor concentrates has arguably struggled to
deliver for decades – namely maintaining a minimal
level of FVIII:C well above the minimum prophylaxis
level (1 iu/dL) defined in the 1960s [20,21]. Analysis of
those living with non-severe hemophilia A in a Dutch
cohort describes the ever decreasing risk of spon-
taneous joint bleeding as the baseline FVIII:C levels
rise through 5 iu/dL then past 10 iu/dL, confirmed by
a recent, large US cohort [22,23]. PWH (severe) and
their families currently require CFC prophylaxis IV train-
ing and CFC supply from early in life, with continuous
and frequent life-long CCC contact to encourage
adherence, evaluate more serious bleeds and oversee
surgical interventions. Musculoskeletal complications
have inevitably occurred in the majority of adults and
centers oversee outcome measurement collection
throughout the decades of life. It is conceivable that
novel agents started early enough in life will circum-
vent the necessity for early, intensive medical involve-
ment, resulting in a more distant relationship with their
CCC akin to current mild hemophilia A cohorts. If these
novel agents do indeed demonstrate a steady hemo-
static threshold and superiority in efficacy, such a dis-
tance from the CCC risks a depersonalization in
hemophilia care. This brings both advantage and dis-
advantage, discussed below. However, a notable early
advantage is the re-establishment of equity in treat-
ment efficacy between those living with or without a
chronic inhibitor. In this particular niche of chronic
inhibitors, novel molecules such as emicizumab (Hem-
Libra®) appear to demonstrate a superior efficacy over
conventional BPA prophylaxis in adults [16,24], albeit
with need for significant caution in times of co-admin-
istration of BPA [25].
Spontaneous or traumatic bleed avoidance with CFC
prophylaxis has been demonstrated to be meaningful
in both children and adults living with severe HA
[6,7]. The stereotyped view of mild hemophilia A is of
being infrequent hospital/emergency department
(ED) attenders, often diagnosed later in life, free of
spontaneous bleed risk with rare need for the expertise
of their CCC. However, in times of crisis, anecdotally,
emergency pathways are often less clear for these indi-
viduals, often presenting later than those with more
severe hemophilia with consequent risk of avoidable
morbidity and potential mortality. This principle is
already borne out in the ‘treated’ and ‘all bleed’
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metrics introduced in novel-agent, open-label clinical
trials [16] which has de-escalated the urgency of hemo-
static treatment for perceived non-serious injuries or
symptoms. This contrasts to the current CFC conven-
tion of ‘treat first, ask later’. Additionally, the majority
of those living with mild hemophilia do not have the
skill to self-administer intravenous factor concentrate
at home or whilst traveling, thus increasing their hospi-
tal dependency at times of crisis. A recent UK cohort of
over 800 non-severe hemophilia A PWH retrospectively
analyzed treatment burden over a 2-year period. Forty-
four percent (377/853) of non-severe PWH required at
least one hemostatic treatment in the 2-year study
period, 79% (296/377) of whom received FVIII CFC
[26]. Despite the Dutch and US papers’ prediction of
minimal spontaneous joint bleeding in the mild hemo-
philia population [22,23], the UK cohort suggests treat-
ment for bleed treatment, surgery or procedures is
more frequent than previously recognized.
Those using novel prophylaxis agents in the future
will still need ‘top up’ on demand treatment with con-
ventional CFC or BPA for significant trauma or pro-
cedures. This introduces a new challenge for treating
hemophilia teams. New educational strategies will be
required to transition PWH to these new agents,
manage their expectations of how active they may
wish to become if their musculoskeletal status allows,
whilst retaining a close enough relationship to keep
the communication pathways open in the event of
emergencies. Over time, with sufficient prophylaxis
efficacy, these patients may not even keep a supply
of CFC or BPA at home at all, as is the case for the
majority of PW non-severe hemophilia. This will
become a re-personalization era, during which treaters
re-focus individuals and families on how to manage
their severe hemophilia, minimizing new risks in the
era of these novel agents whilst highlighting the com-
prehensive care need beyond just CFC supply and
treatment, maintaining true holistic, multidisciplinary
care [27,28].
True primary prophylaxis in severe hemophilia starts
early, often in the first year of life. Complete joint bleed
avoidance is the key to guarantee long-term musculos-
keletal health. However, it is well recognized to be chal-
lenging to implement with CFC, requiring intravenous
access, often by an implanted venous access device
and intensive training of the parents to ultimately be
able to treat at home. Those with a family history and
confirmation of severe hemophilia on the day of birth
without bleed complication currently have an uncer-
tain wait for months until first exposure to CFC. There
are ad hoc ED attendances and often multiple,
emotionally traumatic attempts to administer CFC
intravenously in a small child. There is an ever-
present risk of intracranial hemorrhage in this first
year, in the absence of prophylaxis [29]. The early treat-
ment of these previously untreated patients (PUPs)
requires a systematic surveillance for inhibitory anti-
body responses against the infused therapeutic CFC
[30]. This period is challenging for the treating team
and family, but as a result, the intensity embeds a
solid foundation of trust in the hemophilia care team,
with clear, open and well-tested emergency care path-
ways. A therapeutic agent that could be administered
by a parent more simply than intravenous CFC, e.g.
subcutaneously, avoiding the need for implanted
venous access devices, could enable a true primary
prophylaxis to be instituted earlier for musculoskeletal
protection, additionally reducing ICH risk. For those
with a family history of severe hemophilia, this could/
should arguably be from the day of diagnosis. Earliest
intervention with a novel agent from first day, week
or month of life needs both short- and longer term
study data to demonstrate safety and efficacy in such
young individuals. The efficacy of biphenotypic anti-
body therapy (e.g. emicizumab) is well documented
now in the context of human physiology with a
mature liver [16,31,32] but lacking in the context of
an immature neonatal/infant liver, with lower substrate
levels of both FIX and FX with potential efficacy impli-
cations. Similarly, the novelty of the interfering RNA
(iRNA) therapeutic has accrued data in individuals
with mature livers, albeit with some LFT derangement
in some with a chronic history of HCV [17] A similar
challenge to ‘earliest intervention’ in a neonate with
such a therapeutic demands the necessary PUP-equiv-
alent clinical trial to be performed in the youngest
patients. It is not clear that such studies are planned
as yet. Longer term trials are also required, akin to
the CFC international joint outcome study [6], to
demonstrate long-term MSK benefit of such early inter-
vention. In contrast to the current adult, previously
treated patient (PTP) cohort who will live with the
legacy musculoskeletal damage of the last decades of
treatment, the emerging PUP cohort may benefit
from a more complete, life-long musculoskeletal pro-
tection and bleed avoidance.
Inhibitor occurrence remains the predominant chal-
lenge of implementing prophylaxis in a young boy. If
novel agents offer a potential of true bleed avoidance
and musculoskeletal protection, might they also offer
inhibitor avoidance too? Superficially, this would
seem to be possible given the avoidance of early CFC
exposure. However, the previously cited non-severe
HA data suggests a substantial need for on demand
CFC exposure in non-severe HA [26]. Additionally,
given a novel agent may be implemented as the pro-
phylaxis agent, without sufficient efficacy to treat a sig-
nificant trauma or cover major surgery, these episodes
will require on demand management with CFC
exposure. Gouw et al. have demonstrated an increasing
risk of inhibitor occurrence in the first 50ED to CFC if
prophylaxis is not implemented by 20EDs [33].
Indeed the higher than expected inhibitor rates in
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both arms of the SIPPET randomized controlled trial are
in part attributable to longer on demand exposure in a
majority [9]. Taken together, the on demand exposure
to CFC in the context of novel agent prophylaxis may
paradoxically increase inhibitor rates and also delay
inhibitor occurrence to later in childhood or even adult-
hood depending on frequency of on demand CFC
requirements. This brings additional challenges to the
care team, given the inhibitor screening will be
spread out over years rather than the current months,
more akin to that after CFC exposure in non-severe
HA. However, inhibitor screening in non-severe HA is
already suboptimal with conventional assays [26].
Inhibitor screening in individuals with novel agent
therapeutics on board will need specific assay con-
siderations [25]. We may be at a time when the stan-
dard inhibitor assay (Bethesda) is no longer the first
choice assay and an immunological assay (unaffected
by the novel hemostatic agent), e.g. ELISA, applied for
screening and then a bovine reagent-modified
Bethesda used to determine inhibitory relevance of
ELISA positive results.
If the current estimated 30–45% of individuals to
experience an inhibitor were to arise at a later time
point in childhood, there will be very different chal-
lenges to considering and implementing immune toler-
ance induction (ITI) as the definitive goal of treatment.
Long-term tolerance to either FVIII or FIX remains the
crucial status for a PWH to ensure the most efficacious
hemostatic treatment in a time of crisis, particularly sig-
nificant trauma, surgery or head injury. Additionally, the
normalized or near normalized FVIII:C and FIX:C levels in
recently reported adeno-associated viral (AAV) gene
therapy studies highlight a real, transformational
promise of this one-off intervention in the non-inhibitor
setting [34,35]. Achieving tolerance to wild-type FVIII or
FIX will likely remain a pre-requisite for eligibility for
gene therapy in the medium term.
This evolving landscape of new agents and contin-
ued inhibitor risk will require a very deliberate, re-per-
sonalized care strategy from the current strategies
treaters are familiar with. Conversion to an intensive
intravenous CFC ITI, having had early years on a SC
novel agent prophylaxis agent, will not only have
health economic demands for a heavier, older
patient, but the physical and psychological impact on
the older boy and family will be very different to
those in the younger boys of current practice. Despite
these challenges, it is crucial that as a treating commu-
nity, we do not avoid the short-term challenges of con-
sidering and implementing ITI, thereby guaranteeing
the benefit of long-term tolerance in the majority
[36]. Whether ITI can occur with lower dose CFC, con-
currently with a novel agent prophylaxis agent on
board, is another area requiring additional data, as is
the means by which tolerance would be maintained
thereafter.
Finally, an unintended consequence of delay in first
CFC exposure if novel agents are used for primary pro-
phylaxis is that it affords treaters time in all patients to
describe the F8 genotype and possibly for the first time
start to use immunological polymorphism data in a
more meaningful way within this new time window
[12–15]. Thus it may be that our time to apply stratified
medicine in hemophilia is truly upon us, to identify at
risk individuals, counsel about and possibly intervene
differently to avoid inhibitor occurrence. Whilst for
those older individuals, stratifying access to novel
agent prophylaxis agents initially on bleed phenotypes
after personalized popPK optimization on existing CFC
prophylaxis. This can provide a logical transition to
identify who could/should use new agents early and
enable data acquisition to identify both efficacy and
life quality advantage. Meticulous, collaborative
adverse-event reporting for these emerging cohorts
should be a priority with careful consideration of attri-
butions of causality for any event, including deaths. All
of the scenarios discussed will require proactive re-per-
sonalization of how we counsel, stratify and prescribe
treatments for our patients and families living with
hemophilia in the coming years.
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